Pharmaceutical PV DIV - FSB
Ended Awarded Last action
- Contract number
- SPE2DU26FEMPK
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $123,966
Award facts
- Contract value 100% obligated
- $123,965.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $123,965.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This firm fixed-price delivery order, awarded on December 10, 2025, with an ultimate completion date of December 11, 2025, represents a single transaction under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with DLA. The order carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group maintains SAM registration dating to July 2001 and serves as a critical supplier within the federal pharmaceutical supply chain, distributing a comprehensive range of products including branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables to Department of Defense healthcare facilities.
This delivery order operates under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy through which DLA established multiple regional prime vendor contractors. DMS Pharmaceutical Group's underlying IDC, designated SPE2DR and awarded November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. The PPV-G GEN V program authorizes DLA to issue firm fixed-price delivery orders for pharmaceutical products and medical consumables to support recurring medical supply needs of military healthcare facilities worldwide, positioning DMS Pharmaceutical Group as a key component of Department of Defense global healthcare operations.
Quick answers
Who was awarded contract SPE2DU26FEMPK?
SPE2DU26FEMPK was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 10, 2025.
How much is contract SPE2DU26FEMPK worth?
The government has obligated $123,966 on SPE2DU26FEMPK.
Is contract SPE2DU26FEMPK an order under another contract?
Yes. SPE2DU26FEMPK is a delivery order under SPE2DU25D9517, an indefinite delivery contract.
Was contract SPE2DU26FEMPK competed?
The extent of competition for SPE2DU26FEMPK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award